3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
3
Genitourinary
3
CNS
3
Breast
3
Thoracic
2
Gastrointestinal
2
Dermatologic
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Influenza, Human
1
Interventions
Rituximab
531
Cyclophosphamide
426
Vincristine
219
Doxorubicin
193
fludarabine phosphate
177
Prednisone
167
Etoposide
167
fludarabine
162
Methotrexate
162
Cytarabine
157
Filgrastim
125
Dexamethasone
123
Lenalidomide
121
Granulocyte Colony-Stimulating Factor
116
Whole-Body Irradiation
107
Mycophenolic Acid
99
ibrutinib
97
Bendamustine Hydrochloride
91
Tacrolimus
88
Melphalan
85
Calcium Dobesilate
82
Peripheral Blood Stem Cell Transplantation
80
Bortezomib
80
Busulfan
78
obinutuzumab
64
ofatumumab
59
Radiotherapy
57
Cyclosporine
57
Brentuximab Vedotin
55
Antilymphocyte Serum
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Vaccines
×
Lymphoid
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts